News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,274 Results
Type
Article (13726)
Company Profile (258)
Press Release (242290)
Section
Business (79190)
Career Advice (147)
Deals (13177)
Drug Delivery (28)
Drug Development (50150)
Employer Resources (31)
FDA (5635)
Job Trends (5105)
News (143639)
Policy (10020)
Tag
Academia (900)
Africa (145)
Allergies (30)
Alliances (21407)
Alzheimer's disease (681)
Antibody-drug conjugate (ADC) (31)
Approvals (5598)
Arizona (38)
Artificial intelligence (28)
Asia (16635)
Australia (2776)
Bankruptcy (96)
Best Places to Work (4338)
Biotechnology (215)
C2C Services and Suppliers (10654)
California (1162)
Canada (478)
Cancer (243)
Career advice (128)
CAR-T (33)
Cell therapy (91)
China (83)
Clinical research (38975)
Collaboration (81)
Colorado (34)
Compensation (34)
Connecticut (38)
COVID-19 (976)
Cystic fibrosis (58)
Data (165)
Diabetes (36)
Diagnostics (1156)
Earnings (28358)
Employer resources (29)
Europe (35654)
Events (45734)
Executive appointments (87)
FDA (5733)
Florida (115)
Funding (91)
Gene therapy (76)
Georgia (27)
GLP-1 (259)
Government (1052)
Healthcare (6510)
Hotbed/Location (184269)
Illinois (70)
Indiana (42)
Infectious disease (985)
Inflammatory bowel disease (77)
IPO (7128)
Job creations (856)
Job search strategy (124)
Kansas (52)
Layoffs (177)
Legal (1368)
Lung cancer (55)
Maryland (175)
Massachusetts (944)
Medical device (2521)
Medtech (2522)
Mergers & acquisitions (6041)
Metabolic disorders (125)
Michigan (37)
Minnesota (65)
Neuroscience (779)
New Jersey (310)
New York (376)
NextGen Class of 2024 (1976)
Non-profit (841)
North Carolina (320)
Northern California (513)
Obesity (72)
Ohio (61)
Opinion (86)
Parkinson's disease (29)
Patents (34)
Peanut (27)
Pennsylvania (269)
People (24705)
Pharmaceutical (41)
Phase I (13669)
Phase II (18118)
Phase III (11542)
Pipeline (67)
Postmarket research (843)
Preclinical (5760)
Press Release (30)
Rare diseases (100)
Real estate (1408)
Regulatory (8010)
Research institute (928)
South America (206)
Southern California (483)
Startups (1963)
Texas (104)
United States (4465)
Vaccines (126)
Washington State (149)
Weight loss (56)
Date
Last 7 days (386)
Last 30 days (1164)
Last 365 days (21405)
2024 (14792)
2023 (22427)
2022 (26833)
2021 (27814)
2020 (23366)
2019 (16244)
2018 (11747)
2017 (13753)
2016 (11847)
2015 (14358)
2014 (10397)
2013 (7494)
2012 (7541)
2011 (7621)
2010 (7433)
256,274 Results for "gemini therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity.
June 24, 2024
·
9 min read
Drug Development
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
AnaptysBio, Inc. announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab in patients with generalized pustular psoriasis, a severe orphan disease that is potentially life-threatening if left untreated.
May 9, 2024
·
7 min read
Drug Development
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini.
March 4, 2024
·
5 min read
Drug Development
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02).
June 13, 2024
·
5 min read
Deals
Disc Medicine Announces Completion of Merger with Gemini Therapeutics
Disc Medicine, Inc. announced that its previously-announced merger with Gemini Therapeutics, Inc. closed on December 29, 2022, following the approval of Gemini shareholders.
December 29, 2022
·
8 min read
Biotech Bay
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
Sight Sciences, Inc. announced the acceptance for publication in Clinical Ophthalmology of the prospective, multi-center, three-year GEMINI 2 trial with long-term clinical outcomes for patients treated with the OMNI® Surgical System technology.
December 8, 2023
·
8 min read
BioMidwest
Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study
Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114).
July 12, 2023
·
2 min read
BioMidwest
Orthofix Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures
Orthofix Medical Inc., a leading global spine and orthopedics company, announced the full U.S. commercial launch and successful completion of the first cases with the Galaxy Fixation Gemini™ system.
September 20, 2023
·
5 min read
Biotech Bay
GeminiBio’s Aseptic Assurance System™ Supports Closed System Manufacturing for Cell Therapies
Gemini Bioproducts, LLC today announced the launch of new products designed to improve cell therapy manufacturing processes.
March 14, 2024
·
3 min read
Business
GeminiBio Appoints Mike Guerra to its Board of Directors
Gemini BioProducts Holding, Inc. announced the appointment of Mike Guerra to its Board of Directors.
February 20, 2024
·
3 min read
1 of 25,628
Next